Azenta Life Sciences and Form Bio Announce Strategic Partnership to Advance AAV Gene Therapy Development

Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster.

BURLINGTON, Mass., May 13, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership between GENEWIZ from Azenta Life Sciences, a global provider of multiomics and synthetic solutions services, and Form Bio, a leading artificial intelligence (AI) life sciences technology company, to enhance adeno-associated virus (AAV) gene therapy development through a fully integrated sequencing and data analysis solution.

Read more at prnewswire.com